Advisory Services Network LLC Acquires 3,866 Shares of Allergan plc (AGN)

Advisory Services Network LLC boosted its holdings in shares of Allergan plc (NYSE:AGN) by 148.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,462 shares of the company’s stock after buying an additional 3,866 shares during the period. Advisory Services Network LLC’s holdings in Allergan were worth $1,057,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cable Hill Partners LLC boosted its stake in Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after buying an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. boosted its stake in Allergan by 283.7% during the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after buying an additional 400 shares in the last quarter. Phocas Financial Corp. acquired a new stake in Allergan during the second quarter worth $150,000. BB&T Investment Services Inc. boosted its stake in Allergan by 1,308.2% during the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock worth $139,000 after buying an additional 641 shares in the last quarter. Finally, WFG Advisors LP boosted its stake in Allergan by 20.9% during the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock worth $193,000 after buying an additional 137 shares in the last quarter. Hedge funds and other institutional investors own 79.76% of the company’s stock.

A number of research firms have weighed in on AGN. Bank of America lifted their price target on shares of Allergan from $208.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. ValuEngine downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Credit Suisse Group boosted their target price on shares of Allergan from $214.00 to $215.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Leerink Swann boosted their target price on shares of Allergan from $237.00 to $242.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Finally, Cantor Fitzgerald set a $191.00 target price on shares of Allergan and gave the company a “hold” rating in a research note on Saturday, December 2nd. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $227.23.

In other news, Director Chris W. Bodine acquired 3,030 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was purchased at an average cost of $164.77 per share, with a total value of $499,253.10. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Brent L. Saunders acquired 4,600 shares of the company’s stock in a transaction on Wednesday, December 6th. The shares were purchased at an average cost of $164.74 per share, with a total value of $757,804.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 17,630 shares of company stock valued at $2,890,057 over the last three months. Company insiders own 0.36% of the company’s stock.

Allergan plc (NYSE AGN) opened at $164.04 on Friday. The stock has a market cap of $54,700.00, a PE ratio of -13.68, a P/E/G ratio of 1.16 and a beta of 1.19. The company has a current ratio of 2.04, a quick ratio of 1.88 and a debt-to-equity ratio of 0.41. Allergan plc has a 52-week low of $156.00 and a 52-week high of $256.80.

Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.74 by $0.12. The business had revenue of $4.33 billion for the quarter, compared to the consensus estimate of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.90 EPS. analysts forecast that Allergan plc will post 15.57 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a dividend of $0.72 per share. This is an increase from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date is Tuesday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.76%. Allergan’s dividend payout ratio is -23.35%.

COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/18/advisory-services-network-llc-acquires-3866-shares-of-allergan-plc-agn.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply